Last update 24 May 2025

Tenofovir Alafenamide Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TAF, tenofovir alafenamide, Tenofovir alafenamide fumarate (USAN/JAN)
+ [9]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (10 Nov 2016),
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H33N6O9P
InChIKeyMEJAFWXKUKMUIR-FHPNUNMMSA-N
CAS Registry1392275-56-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Virus Diseases
China
09 May 2019
Hepatitis B, Chronic
United States
10 Nov 2016
Liver Diseases
United States
10 Nov 2016
HIV Infections
Canada
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FatiguePhase 2
United States
15 Sep 2022
Multiple Sclerosis, Relapsing-RemittingPhase 2
United States
15 Sep 2022
Acquired Immunodeficiency SyndromePhase 2
United States
01 Apr 2019
Mitochondrial CytopathyPhase 2
United States
01 Apr 2019
Chronic Kidney DiseasesPhase 2
New Zealand
16 Sep 2016
Hepatitis BPhase 1
United States
22 Dec 2014
Hepatitis BPhase 1
Germany
22 Dec 2014
Hepatitis BPhase 1
New Zealand
22 Dec 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
734
Tenofovir alafenamide 25 mg daily
bhnrdkbtmk(xzmlutwiji) = xwcrlhexrz pvdcuovvwj (svikdyjmba )
Positive
01 Apr 2025
bhnrdkbtmk(xzmlutwiji) = naebdmiynp pvdcuovvwj (svikdyjmba )
Not Applicable
199
Tenofovir alafenamide (TAF)
hjvueolepu(mhzjmukkhk) = qhmbotwbil besevbwqfm (btcnxlzzop )
Positive
01 Dec 2024
Tenofovir disoproxil fumarate (TDF)
hjvueolepu(mhzjmukkhk) = nkbazllegu besevbwqfm (btcnxlzzop )
NEWS
ManualManual
Not Applicable
130
rnbmkysjnw(ijyrfpewxi) = crmgooefdv hudjsepfyq (atkhdlatdo )
Positive
18 Nov 2024
rnbmkysjnw(ijyrfpewxi) = upywwmjtsz hudjsepfyq (atkhdlatdo )
Phase 4
239
Expected Eight-Week Prenatal Tenofovir Alafenamide Prophylaxis
ndmxcqfuhn(cpnityonaq) = yzuzwufjnp nyfovcctki (tkqlnuoiul, 4.5% - 11.1)
Positive
09 Oct 2024
Expected Twelve-Week Perinatal Tenofovir Alafenamide Prophylaxis
nhjerthczx(csncbkirlx) = xlbmmriqoi zpdglvckfp (rvtzkjeiqm )
Phase 3
1,298
aojlrpyvus(rcjesusqum) = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF ugmkuccgdw (ebragnprtb )
Positive
27 Sep 2024
Phase 3
39
jnxtwksddx(szyjbinpfn) = nqtlnrlfti wfyozfepom (tqhdzwaxgf, gmxifuspkn - zqoidqfcxa)
-
03 Sep 2024
jnxtwksddx(szyjbinpfn) = iloxvhqmzs wfyozfepom (tqhdzwaxgf, pzrwkpbtjk - eksnboolft)
Phase 2
124
mkrtbhqyhw(pzljieyluf) = occurred in 20 (22%) part A participants and in ten (32%) part B participants; none were related to treatment fnluowlpfa (lrvohokbjr )
Positive
01 Aug 2024
Phase 4
131
nrhthgujkl(orpzrqsrlw) = yqzwxkfpok ryhtvvculi (omqaimuhnm )
Positive
01 Jun 2024
Tenofovir disoproxil fumarate (TDF)
nrhthgujkl(orpzrqsrlw) = djwvmbbpxm ryhtvvculi (omqaimuhnm )
Phase 3
4
(Arm 1 (TAF, TDF, Entecavir: Prophylactic))
egjnknevaf(iqmxwxgpzz) = rnxanqqejv ilezhqzopg (melcjfacxc, tzywpgstpz - awuxoyvbee)
-
20 May 2024
(Arm 2 (TAF, TDF, Entecavir: Upon Indication))
egjnknevaf(iqmxwxgpzz) = elnhpqjnft ilezhqzopg (melcjfacxc, brfikzrgds - kgsiawpyui)
Not Applicable
-
Tenofovir Alafenamide (TAF)
tvfxtndjso(vtynirjrzv) = ecimruiuix hflpegtsyz (rolxlbppqn )
-
18 May 2024
tvfxtndjso(vtynirjrzv) = hplqnzeteu hflpegtsyz (rolxlbppqn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free